Unknown

Dataset Information

0

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.

ABSTRACT: Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Here we show that the size of the EGFR T790M-positive clone impacts response to osimertinib. T790M subclonality, as assessed by a retrospective NGS analysis of 289 baseline plasma ctDNA samples from T790M-positive advanced NSCLC patients from the AURA3 phase III trial, is associated with shorter progression-free survival (PFS), both in the osimertinib and the chemotherapy-treated patients. Both baseline and longitudinal ctDNA profiling indicate that the T790M subclonal tumours are enriched for PIK3CA alterations, which we demonstrate to confer resistance to osimertinib in vitro that can be partially reversed by PI3K pathway inhibitors. Overall, our results elucidate the impact of tumour heterogeneity on response to osimertinib in advanced stage NSCLC patients and could help define appropriate combination therapies in these patients.

SUBMITTER: Vaclova T 

PROVIDER: S-EPMC7979775 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.

Vaclova Tereza T   Grazini Ursula U   Ward Lewis L   O'Neill Daniel D   Markovets Aleksandra A   Huang Xiangning X   Chmielecki Juliann J   Hartmaier Ryan R   Thress Kenneth S KS   Smith Paul D PD   Barrett J Carl JC   Downward Julian J   de Bruin Elza C EC  

Nature communications 20210319 1

Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Here we show that the size of the EGFR T790M-positive clone impacts response to osimertinib. T790M subclonality, as assessed by a retrospective NGS analysis of 289 baseline plasma ctDNA samples from T790M-positive advanced NSCLC patients from the AURA3 phase III trial, is associated with shorter progression-free  ...[more]

Similar Datasets

Unknown Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
| S-EPMC5709185 | biostudies-literature
Unknown The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
| S-EPMC5354886 | biostudies-literature
Unknown Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
| S-EPMC4830020 | biostudies-literature
Unknown Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
| S-EPMC3389159 | biostudies-literature
Unknown Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.
| S-EPMC10643699 | biostudies-literature
Unknown ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
| S-EPMC4367691 | biostudies-literature
Unknown Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
| S-EPMC4155006 | biostudies-literature
Unknown TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
| S-EPMC4474554 | biostudies-literature
Unknown Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
| S-EPMC5989837 | biostudies-literature
Unknown AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer.
| S-EPMC8356077 | biostudies-literature